UBS Group’s Castle Biosciences CSTL Stock Holding History
Bought
Maintained
Sold
Other funds holding CSTL
UBS Group's CSTL Position: Q3 2026 in Review
UBS Group reduced its Castle Biosciences (CSTL) stake by 13% in Q3 2026, selling an estimated $344K and leaving 77,983 shares worth $2.77M. The position accounts for ﹤0.01% of the portfolio, ranked #4722.
UBS Group first reported a position in CSTL in Q3 2019 and has held it in 29 quarters since. The position peaked at $21.7M in Q4 2024. 202 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.
- UBS Group held 77,983 shares of Castle Biosciences worth $2.77M as of Q3 2026.
- UBS Group sold 11,385 Castle Biosciences shares in Q3 2026, an estimated $344K.
- Castle Biosciences made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #4722 holding.
- UBS Group first reported a position in Castle Biosciences in Q3 2019 and has held it in 29 quarters since.
- UBS Group's Castle Biosciences position peaked at $21.7M in Q4 2024.
- 202 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.